Eli Lilly will invest an additional $20 million in Novast Laboratories, Ltd., a Nanjing company that makes generic and specialty pharmaceuticals. A few years ago, Lilly allocated a part of its $100 million China VC fund to Novast. With the new investment, Novast and Lilly will together develop a portfolio of branded generic drugs for the China market. In the future, Novast may manufacture the innovative drugs that Lilly develops for China and other Asian countries. More details.... Stock Symbol: (NYSE: LLY) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});